

Supporting Information

Thiamine pyrophosphate stimulates acetone activation by *Desulfococcus biacutus* as monitored by a fluorogenic ATP analogue

Olga B. Gutiérrez Acosta,^{‡a} Norman Hardt,^{‡b} Stephan M. Hacker,^b Tobias Strittmatter,^b Bernhard Schink^{*a}, Andreas Marx^{*b}

^a Department of Biology, Konstanz Research School Chemical Biology, University of Konstanz, Universitätsstr. 10, 78457 Konstanz, Germany. E-mail: Bernhard.Schink@uni-konstanz.de; Fax: +49 7531 88 4047; Tel: +49 7531 88 2140

^b Department of Chemistry, Konstanz Research School Chemical Biology, University of Konstanz, Universitätsstr. 10, 78457 Konstanz, Germany. Email: Andreas.Marx@uni-konstanz.de; Fax: +49 7531 88 5140; Tel: +49 7531 88 5139

27

28 **Table of Contents**

29 General experimental details 3

30 Synthesis of Compounds 4

31 γ -(6-Azidohexyl)-2-(5-aminopent-1-yn-1-yl)-adenosine-triphosphate **2** 1

32 γ -(6-Azidohexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-triphosphate **3** 1

33 γ -(6-Aminohexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-triphosphate **4**..... 1

34 γ -(6-Sulfo-cyanine3-amidohehexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-triphosphate **1**..... 1

35 General procedures 8

36 SVPD cleavage 8

37 Fluorescence spectra 8

38 HPLC analysis 8

39 HRMS characterisation of probe **1** and its cleavage products **5** and **6** after SVPD cleavage 8

40 Cell cultures 9

41 Preparation of cell extract 9

42 Reaction of probe **1** in cell extract 9

43 Fluorescent read out 10

44 HPLC analysis of the assay mixtures 10

45 HRMS characterisation of probe **1** and its cleavage products after incubation in cell extract 10

46 Literature 11

47

48

49

50

51

52

53 **General experimental details**

54 All temperatures quoted are uncorrected. All reagents were commercially available
55 and used without further purification. All solvents were dried over molecular sieves
56 and used directly without further purification. All reactions were conducted under
57 exclusion of air and moisture. For medium pressure liquid chromatography (MPLC), a
58 Büchi unit with a Büchi controller C-620, two pumps C-605, a UV monitor C-630 ($\lambda =$
59 254 nm) and fraction collector C-660 was used. For the purification of nucleosides
60 and nucleotides, a 310-25 LiChroprep® RP-18 ready-to-use column (Merck, 40-63
61 mm) with a linear gradient (5 to 100%) of acetonitrile in 50 mM aqueous
62 triethylammonium acetate (TEAA buffer, pH 7.0) was used. Reversed phase high
63 pressure liquid chromatography (RP-HPLC) was performed using a Shimadzu unit.
64 For the purification of nucleotides a EC 250/4 NUCLEODUR 100-5 C18 ec
65 (Macherey-Nagel), VP 250/10 NUCLEODUR 100-5 C18 ec (Macherey-Nagel) or VP
66 250/21 NUCLEODUR C18 HTec, 5 μ m (Macherey-Nagel) column and a linear
67 gradient (5 to 100%) of acetonitrile in 50 mM TEAA buffer (pH 7.0) was used. NMR
68 spectra: Bruker Avance III 400 MHz spectrometer and Bruker Avance III 600 MHz
69 spectrometer. ^1H and ^{13}C chemical shifts are reported relative to the residual solvent
70 peak and are given in ppm (δ). A BBFOplus probe with actively shielded z-gradient
71 was used with its inner (BB-) coil tuned to ^{19}F and ^{31}P , respectively. Flash
72 chromatography: Merck silica gel G60. TLC: Merck precoated plates (silica gel 60
73 F₂₅₄). ESI-IT: Bruker Esquire 3000 plus. HRMS: Bruker Daltronics micrOTOF-Q II
74 ESI-Qq-TOF. The reported yield refers to the analytically pure substance and has not
75 been optimized. Compound **2** was synthesized according to the corresponding
76 literature. Snake venom phosphodiesterase (SVPD) was purchased from

77 Worthington Biochemical Corporation. For fluorescent measurements, a Perkin Elmer
78 Luminescence Spectrometer LS50 was used.

79

80 **Synthesis of Compounds**

81 **γ -(6-Azidohexyl)-2-(5-aminopent-1-yn-1-yl)-adenosine-triphosphate 2**

82 Nucleotide **2** was synthesized according to Hardt *et. al.*^[1]

83

84 **γ -(6-Azidohexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-triphosphate 3**

85 Compound **2** (30.0 μ mol, 1 eq.) was dissolved in 5 mL 0.1M NaHCO₃ (pH 8.7) and
86 eclipse-NHS (50.0 mg, 102.1 μ mol, 3.4 eq.), dissolved in dry DMF (1.9 mL), was
87 added and stirred at room temperature overnight. The solvents were evaporated
88 under reduced pressure. The compound was purified by MPLC. Fractions containing
89 the product were evaporated and further purified by RP-HPLC. The solvent was
90 evaporated and the product repeatedly freeze-dried from water to give 7.7 μ mol
91 (26%) of compound **3**.

92 ¹H NMR (MeOD-d₄, 600 MHz): δ 8.65 (s, 1H, H8), 8.35 (d, J = 2.3 Hz, 1H, H-Ar₂-
93 eclipse), 8.16 (dd, J = 8.9, 2.3 Hz, 1H, H-Ar₂-eclipse), 7.87 (d, J = 9.1 Hz, 2H, H-Ar₁-
94 eclipse), 7.76 (d, J = 8.9 Hz, 1H, H-Ar₂-eclipse), 6.83 (d, J = 9.2 Hz, 2H, H-Ar₁-
95 eclipse), 6.05 (d, J = 5.2 Hz, 1H, H1'), 4.62 (t, J = 5.0 Hz, 1H, H2'), 4.54 (t, J = 4.3
96 Hz, 1H, H3'), 4.36 – 4.30 (m, 1H, H5'a), 4.30 – 4.22 (m, 2H, H4', H5'b), 4.01 (q, J =
97 6.1 Hz, 2H, CH₂-linker), 3.52 (t, J = 7.5 Hz, 2H, CH₂-linker), 3.36 (t, J = 6.6 Hz, 2H,
98 CH₂-linker), 3.23 (t, J = 6.9 Hz, 2H, CH₂-linker), 3.09 (s, 3H, CH₃-eclipse), 2.50 (t, J =
99 7.0 Hz, 2H, CH₂-linker), 2.32 (t, J = 7.1 Hz, 2H, CH₂-linker), 2.02 – 1.91 (m, 2H, CH₂-
100 linker), 1.84 (p, J = 6.8 Hz, 2H, CH₂-linker), 1.68 – 1.57 (m, 2H, CH₂-linker), 1.58 –
101 1.48 (m, 2H, CH₂-linker), 1.46 – 1.32 (m, 4H, 2x CH₂-linker).

102 ^{13}C NMR (MeOD- d_4 , 151 MHz): δ 175.41, 156.20, 154.69, 154.34, 150.72, 148.46,
103 145.47, 142.11, 134.64, 127.93, 126.78, 123.87, 119.28, 119.06 112.68, 89.05,
104 85.56 (d, $J_{\text{C-P}} = 9.2$ Hz), 80.76, 76.49, 71.63, 67.27 (d, $J_{\text{C-P}} = 6.1$ Hz), 66.41 (d, $J_{\text{C-P}} =$
105 6.4 Hz), 52.67, 52.40, 39.82, 38.77, 33.86, 31.63 (d, $J_{\text{C-P}} = 8.1$ Hz), 29.86, 28.81,
106 27.55, 26.43, 24.07, 17.56.

107 ^{31}P NMR (MeOD- d_4 , 162 MHz): δ -11.13 (d, $J = 17.4$ Hz, 1P), -11.45 (d, $J = 19.0$ Hz,
108 1P), -22.94 (t, $J = 17.9$ Hz, 1P).

109 HR-ESI-MS: found: 1070.2238; calculated: 1070.2238 (M-H^+ , $\text{C}_{38}\text{H}_{48}\text{ClN}_{13}\text{O}_{16}\text{P}_3^-$);
110 deviation: 0.1 ppm.

111

112 γ -(6-Aminohexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-triphosphate **4**

113 Compound **3** (7.7 μmol , 1 eq.) was dissolved in 5 mL water/methanol/triethylamine
114 (0.5:1.0:0.5) and tris(2-carboxyethyl)phosphine (25.0 mg, 99.9 μmol , 13.0 eq.),
115 dissolved in water (0.5 mL), was added rapidly and stirred at room temperature for 4
116 hours. The solvents were evaporated under reduced pressure. The compound was
117 purified by RP-HPLC. Fractions containing the product were evaporated and the
118 product repeatedly freeze dried from water to give 4.4 μmol (57%) of compound **4**.

119 ^1H NMR (MeOD- d_4 , 600 MHz): δ 8.63 (s, 1H, H8), 8.33 (d, $J = 2.4$ Hz, 1H, H-Ar₂-
120 eclipse), 8.14 (dd, $J = 8.9, 2.4$ Hz, 1H, H-Ar₂-eclipse), 7.85 (d, $J = 9.2$ Hz, 2H, H-Ar₁-
121 eclipse), 7.74 (d, $J = 8.9$ Hz, 1H, H-Ar₂-eclipse), 6.82 (d, $J = 9.2$ Hz, 2H, H-Ar₁-
122 eclipse), 6.03 (d, $J = 4.0$ Hz, 1H, H1'), 4.59 – 4.55 (m, 2H, H2', H3'), 4.34 – 4.29 (m,
123 1H, H5'a), 4.29 – 4.19 (m, 2H, H4', H5'b), 4.03 – 3.93 (m, 2H, CH₂-linker), 3.55 –
124 3.48 (m, 2H, CH₂-linker), 3.35 (t, $J = 6.7$ Hz, 2H, CH₂-linker), 3.09 (s, 3H, CH₃-
125 eclipse), 2.96 (t, $J = 6.9$ Hz, 2H, CH₂-linker), 2.48 (t, $J = 7.0$ Hz, 2H, CH₂-linker), 2.31
126 (t, $J = 7.1$ Hz, 2H, CH₂-linker), 2.00 – 1.92 (m, 2H, CH₂-linker), 1.83 (p, $J = 6.9$ Hz,

127 2H, CH₂-linker), 1.72 – 1.64 (m, 2H, CH₂-linker), 1.61 – 1.54 (m, 2H, CH₂-linker), 1.46
128 – 1.40 (m, 4H, 2x CH₂-linker).

129 ¹³C NMR (MeOD-d₄, 151 MHz): δ 175.36, 156.96, 154.67, 154.32, 150.75, 148.44,
130 147.68, 145.46, 141.69, 134.65, 127.90, 126.77, 123.83, 119.49, 119.02 112.65,
131 89.27, 87.48, 85.30 (d, J_{C-P} = 9.2 Hz), 81.59, 76.54, 71.22, 66.18 (d, J_{C-P} = 6.4 Hz),
132 66.11 (d, J_{C-P} = 4.5 Hz), 52.65, 40.12, 39.83, 38.77, 33.85, 30.61 (d, J_{C-P} = 7.6 Hz),
133 28.90, 28.03, 25.88, 25.58, 24.07, 17.52.

134 ³¹P NMR (MeOD-d₄, 162 MHz): δ -10.63 (d, J = 19.0 Hz, 1P), -11.34 (d, J = 18.9 Hz,
135 1P), -22.02 – -22.96 (m, 1P).

136 HR-ESI-MS: found: 1044.2354; calculated: 1044.2333 (M-H⁺, C₃₈H₅₀CIN₁₁O₁₆P₃⁻);
137 deviation: 2.0 ppm.

138

139 **γ-(6-Sulfo-cyanine3-amidohexyl)-2-(5-eclipse-amidopent-1-yn-1-yl)-adenosine-**
140 **triphosphate 1**

141 Compound **4** (4.4 μmol, 1 eq.) was dissolved in 1 mL 0.1 M NaHCO₃ (pH 8.7) and
142 sulfo-cyanine3-NHS (25.0 mg, 34.4 μmol, 7.8 eq.), dissolved in dry DMF (1.0 mL),
143 was added and stirred at room temperature overnight. The solvents were evaporated
144 under reduced pressure. The compound was purified by MPLC. Fractions containing
145 the product were evaporated and further purified by RP-HPLC. The solvent was
146 evaporated and the product repeatedly freeze-dried from water to give 3.5 μmol
147 (80%) of compound **1**.

148 ¹H NMR (MeOD-d₄, 600 MHz): δ 8.68 (s, 1H, H8), 8.46 (t, J = 13.5 Hz, 1H, H-β-Cy3),
149 8.36 (d, J = 2.3 Hz, 1H, H-Ar₂-eclipse), 8.16 (dd, J = 8.9, 2.4 Hz, 1H, H-Ar₂-eclipse),
150 7.98 – 7.89 (m, 4H, H-Ar-Cy3), 7.86 (d, J = 9.1 Hz, 2H, H-Ar₁-eclipse), 7.76 (d, J =
151 8.9 Hz, 1H, H-Ar₂-eclipse), 7.40 (d, J = 8.7 Hz, 1H, H-Ar-Cy3), 7.39 (d, J = 8.7 Hz,

152 1H, H-Ar-Cy3), 6.84 (d, $J = 9.2$ Hz, 2H, H-Ar₁-eclipse), 6.46 (d, $J = 13.4$ Hz, 1H, H- α -
153 Cy3), 6.42 (d, $J = 13.4$ Hz, 1H, H- α' -Cy3), 6.08 (d, $J = 6.0$ Hz, 1H, H1'), 4.85 – 4.70
154 (m, 1H, H-2'), 4.58 – 4.50 (m, 1H, H3'), 4.35 – 4.28 (m, 1H, H5'a), 4.27 – 4.23 (m,
155 1H, H4'), 4.23 – 4.16 (m, 3H, H5'b, CH₂-linker), 4.16 – 4.08 (m, 2H, CH₂-linker), 4.04
156 – 3.92 (m, 2H, CH₂-linker), 3.55 – 3.48 (m, 2H, CH₂-linker), 3.34 – 3.28 (m, 2H, CH₂-
157 linker), 3.13 (t, $J = 6.7$ Hz, 2H, CH₂-linker), 3.09 (s, 3H, CH₃-eclipse), 2.38 (t, $J = 7.0$
158 Hz, 2H, CH₂-linker), 2.31 (t, $J = 7.1$ Hz, 2H, CH₂-linker), 2.22 (t, $J = 7.4$ Hz, 2H, CH₂-
159 linker), 1.97 – 1.92 (m, 2H, CH₂-linker), 1.83 – 1.80 (m, 2H, CH₂-linker), 1.78 – 1.72
160 (m, 12H, 4x CH₃-Cy3), 1.71 -1.63 m, 2H, CH₂-linker), 1.62 – 1.53 (m, 2H, CH₂-linker),
161 1.52 – 1.43 (m, 4H, 2x CH₂-linker), 1.39 (t, $J = 7.2$ Hz, 3H, CH₃-ethyl), 1.36 – 1.27 (m,
162 6H, 3x CH₂-linker).

163 ¹³C NMR (MeOD-d₄, 151 MHz): δ 176.57, 176.36, 175.80, 175.34, 156.94, 154.71,
164 154.30, 152.73, 151.20 148.43, 147.66, 145.42, 144.64, 144.22, 144.04, 143.99,
165 142.38, 142.23, 134.64, 128.27, 127.96, 126.84, 123.92, 121.47, 121.42, 119.42,
166 119.05, 112.74, 112.21, 112.03, 104.63, 104.49, 88.51, 87.41, 81.64, 76.20, 67.00,
167 52.68, 50.70, 50.64, 45.51, 40.76, 40.30, 39.77, 38.86, 36.82, 33.84, 31.46 (d, $J_{C-P} =$
168 7.7 Hz), 30.17, 28.29, 28.99, 28.26, 28.16, 27.53, 27.42, 26.69, 26.40, 24.12, 17.48,
169 12.73.

170 ³¹P NMR (MeOD-d₄, 162 MHz): δ -10.52 (d, $J = 17.4$ Hz, 1P), -11.03 (d, $J = 17.0$ Hz,
171 1P), -20.56 – -21.40 (m, 1P).

172 HR-ESI-MS: found: 827.7091; calculated: 827.7107 (M-2H⁺, C₆₉H₈₅CIN₁₃O₂₃P₃S₂²⁻);
173 deviation: 1.9 ppm.

174

175 **General procedures**

176 **SVPD cleavage:** 2.5 μL (1 mM) of the corresponding doubly dye-labeled ATP
177 analogue and 3.13 μL SVPD (0.2 mg mL^{-1}) were processed in a total volume of 25 μL
178 of NEB buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl_2 , 1 mM DTT, pH 7.9) for
179 30 min at 30°C . Negative controls were performed in the absence of SVPD.

180

181 **Fluorescence spectra:** For fluorescence measurements the SVPD reactions were
182 diluted with 3 mL 1x PBS buffer and the fluorescence spectra of the crude reaction
183 solution was measured. Excitation of sulfo-Cy3 was performed using a wavelength of
184 532 nm.

185

186 **HPLC analysis:** For HPLC analysis the SVPD reactions were diluted with 275 μL of
187 H_2O and separated by analytical RP-HPLC (a linear gradient of acetonitrile in 50 mM
188 aqueous triethylammonium acetate (TEAA buffer, pH 7.0) was used). RP-HPLC
189 analytics were visualized using 2D-plots. Fractions were collected and further
190 characterized by HRMS.

191

192 **HRMS characterisation of probe 1 and its cleavage products 5 and 6 after SVPD**

193 **cleavage:** Control without SVPD: HR-ESI-MS **1**: found: 827.7125; calculated:
194 827.7107 ($\text{M}-2\text{H}^+$, $\text{C}_{69}\text{H}_{85}\text{ClN}_{13}\text{O}_{23}\text{P}_3\text{S}_2^{2-}$); deviation: 2.2 ppm. Reaction with SVPD:
195 HR-ESI-MS **5**: found: 443.6127; calculated: 443.6138 ($\text{M}-\text{H}^{2+}$, $\text{C}_{37}\text{H}_{52}\text{N}_3\text{O}_{14}\text{P}_2\text{S}_2^{2-}$);
196 deviation: 2.5 ppm. HR-ESI-MS **6**: found: 785.1978; calculated: 785.1958 ($\text{M}-\text{H}^+$,
197 $\text{C}_{32}\text{H}_{35}\text{ClN}_{10}\text{O}_{10}\text{P}^-$); deviation: 2.5 ppm.

198

199 **Cell cultures:** The sulfate-reducing bacterium *Desulfococcus biacutus* strain
200 KMRActS was grown in freshwater mineral medium as described before. [2, 3] The
201 medium was reduced with 1 mM sulfide, buffered with CO₂-bicarbonate, and adjusted
202 to a final pH of 7.2. Cells were cultured in 1 L flasks with medium supplemented with
203 5 mM acetone as sole carbon source and 10 mM sulfate as the electron acceptor.
204 Cultures were incubated under a strictly anoxic N₂-CO₂ (80/20) atmosphere at 30°C
205 in the dark.

206

207 **Preparation of cell extract:** Cells of *D. biacutus* were harvested in the late
208 exponential growth phase at an optical density of 0.3 (OD₆₀₀). All experiments with
209 cell extract were done under strictly anoxic conditions. Cells were centrifuged at
210 6,000 x g at 4°C and the pellet was washed at least twice with 50 mM potassium
211 phosphate (KP) buffer, pH 7.2, supplemented with 3 mM dithioerythritol as reducing
212 agent. The cell pellet was resuspended in the same buffer plus 0.5 mg DNase mL⁻¹
213 and 1 mg mL⁻¹ of complete protease inhibitor cocktail (Complete Mini, EDTA-free
214 protease inhibitor cocktail tablets, Roche Diagnostics GmbH). Cells were disrupted
215 by passing them twice through a cooled French pressure cell at 100 MPa. Cell debris
216 and un-opened cells were removed by centrifugation at 27,000 x g for 20 min at 4°C.

217

218 **Reaction of probe 1 in cell extract:** Cell extract of *D. biacutus* prepared after
219 growth on acetone was used to test the carbonylation reaction. All enzyme assays
220 were carried out under strictly anoxic conditions. The buffer solution was the same as
221 described for washing the cells pellet, and contained 1 g L⁻¹ NaCl, 0.6 g L⁻¹ MgCl₂
222 H₂O and 3 mM dithioerythritol. The enzyme reaction was tested in Eppendorf tubes
223 sealed with a rubber stopper. Concentrations of substrates were 1 mM acetone, 0.5
224 mM ATP analogue 1, 2 mM TPP and 10% CO in the headspace. The reaction was

225 incubated for 1 hour at 30°C. For the time course experiments, samples were taken
226 at different time intervals with syringes previously flushed with N₂. Addition of 2 mM
227 CoA and 4mM NAD⁺ to the same reaction system was also tested. Before testing
228 the effect of the addition of those cofactors, cell extract was pretreated for removal of
229 small molecules by passing freshly prepared sample protein by gravity through a
230 SephadexTM G-25 column (illustra NAP-25 Columns; GE Healthcare). The same KP
231 buffer described above was used for column equilibration and protein elution. All
232 reactions were stopped with 2 mM EDTA solution. Each reaction condition was run in
233 triplicate.

234

235 **Fluorescent read out:** From each sample, 10 μL aliquots were uniformly mixed with
236 90 μL Milli Q water and placed onto a dark 96 well plate for fluorescence
237 measurement. Dilutions were done as it was required. The procedure was run three
238 times for each triplicate. Standards of sulfo-Cy3 were prepared in order to quantify
239 the rate and specific activity of hydrolysis of ATP probe 1.

240

241 **HPLC analysis of the assay mixtures:** Protein was precipitated by the addition of
242 10 μL of 2 M H₂SO₄, and removed by centrifugation at 10,000 x g. The supernatant
243 was analysed by analytical RP-HPLC as described above. Fractions containing ATP
244 fragments were collected and further characterized by HRMS.

245

246 **HRMS characterisation of probe 1 and its cleavage products after incubation in**
247 **cell extract:** Fractions were collected during RP-HPLC separation and analysed by
248 HRMS. Control under nitrogen: HR-ESI-MS 1: found: 827.7091; calculated: 827.7107
249 (M-2H⁺, C₆₉H₈₅ClN₁₃O₂₃P₃S₂²⁻); deviation: 1.9 ppm. Reaction under CO: HR-ESI-MS

250 **5:** found: 888.2377; calculated: 888.2360 (M-H⁺, C₃₇H₅₃N₃O₁₄P₂S₂⁻); deviation: 1.9
251 ppm.

252

253

254 **Literature**

255 [1] (a) Hacker, S. M., Hardt, N., Buntru, A., Pagliarini, D., Mockel, M., Mayer, T.
256 U., Scheffner, M., Hauck, C. R., and Marx, A. (2013) Fingerprinting differential
257 active site constraints of ATPases. *Chemical Science* 4, 1588-1596.

258 (b) Hardt, N., Hacker, S. M., and Marx, A. (2013) Synthesis and fluorescence
259 characteristics of ATP-based FRET probes, *Organic & biomolecular chemistry*
260 11, 8298-8305.

261 [2] Platen, H., Temmes, A., and Schink, B. (1990) Anaerobic degradation of
262 acetone by *Desulfococcus biacutus* spec. nov., *Archives Microbiology* 154,
263 355-361.

264 [3] Gutierrez Acosta, O. B., Hardt, N., and Schink, B. (2013) Carbonylation as a
265 key reaction in anaerobic acetone activation by *Desulfococcus biacutus*,
266 *Applied and Environmental Microbiology* 79, 6228-6235.